HUMAN MESENCHYMAL STEM CELL-CONDITIONED MEDIUM FOR USE IN TREATMENT OF CHRONIC HEART-LUNG AND VASCULAR DISEASES, IN PARTICULAR, OF PULMONARY ARTERIAL HYPERTENSION (PAH)

The present invention relates to the field of medical treatment of chronic disease with stem-cell derived products, in particular, human mesenchymal stem cell-derived treatment of chronic heart-lung and vascular diseases. The inventors provide human mesenchymal stem cell-conditioned medium, such as human umbilical cord mesenchymal stem cell-conditioned medium (HUMSC-CM) for use in treatment of chronic heart-lung and vascular diseases, in particular, pulmonary hypertension (PH, groups 1-5), such as pulmonary arterial hypertension (PAH; group 1 PH according to World Symposium on Pulmonary Hypertension 2018, http://www.wsphassociation.org/). The invention also provides a method of treating chronic heart-lung-vascular diseases by means of administering such conditioned medium intravascularily..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 06. Dez. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

HANSMANN GEORG [VerfasserIn]
HASS RALF [VerfasserIn]
GIERA MARTIN [VerfasserIn]
RALSER MARKUS [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
bio
C12N: Microorganisms or enzymes; compositions thereof; pr (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-12-06, Last update posted on www.tib.eu: 2023-12-26, Last updated: 2023-12-29

Patentnummer:

EP4285915

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA01872390X